CAP Economic Affairs Committee member Jan Nowak, MD, FCAP, spoke to 360Dx about CMS pricing remaining the same and the negative impact that will have on testing.
For the full article click here: CMS Preliminary Pricing for Genomic Procedures Raises Alarm Among Stakeholders